Mark G. Lebwohl

Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.

Lebwohl's books include the book on dermatologic therapy, ''Treatment of Skin Disease'' (), as well as ''Atlas of the Skin and Systemic Disease'' (). He has authored more than 500 publications, multiple book chapters and has been named as one of New York Magazine’s “Best Doctors” every year since the inception of the annual list. Dr. Brian S. Kim is director of a Center for Neuroinflammation and Sensation named in Mark Lebwohl's honor at Icahn School of Medicine at Mount Sinai. Provided by Wikipedia
Showing 1 - 20 results of 25 for search 'Mark Lebwohl', query time: 0.07s Refine Results
  1. 1
    Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis

    Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis by Nora Koutruba, Jason Emer, Mark Lebwohl

    Published 2010-03-01
    Get full text
    Article
  2. 2
    Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

    Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence by Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl

    Published 2020-04-01
    Get full text
    Article
  3. 3
    Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

    Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence by Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl

    Published 2020-05-01
    Get full text
    Article
  4. 4
    New onset and exacerbation of psoriasis after COVID-19 vaccination

    New onset and exacerbation of psoriasis after COVID-19 vaccination by Nancy Wei, BA, Mindy Kresch, BS, Emily Elbogen, PA-C, Mark Lebwohl, MD

    Published 2022-01-01
    Get full text
    Article
  5. 5
    “COVID arm”: A reaction to the Moderna vaccine

    “COVID arm”: A reaction to the Moderna vaccine by Nancy Wei, MS, Mary Fishman, MD, Debra Wattenberg, MD, Marsha Gordon, MD, Mark Lebwohl, MD

    Published 2021-04-01
    Get full text
    Article
  6. 6
    Stasis dermatitis: A challenging patient journey

    Stasis dermatitis: A challenging patient journey by Mark Lebwohl, Robert S. Kirsner, David J. Margolis, Benjamin Barankin, Takashi Hashimoto, Juliana M. Canosa, Amy Cha

    Published 2023-12-01
    Get full text
    Article
  7. 7
    Patient perspective on symptoms of Notalgia paresthetica: subpopulation results from the Neuropathic Itch Patient Survey (NIRVE)

    Patient perspective on symptoms of Notalgia paresthetica: subpopulation results from the Neuropathic Itch Patient Survey (NIRVE) by Brian S. Kim, Jennifer A. Mohawk, Sherri So, Joshua Cirulli, Joana Goncalves, Joseph C. Punzalan, Mark Lebwohl

    Published 2024-12-01
    Get full text
    Article
  8. 8
    Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study

    Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study by Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl

    Published 2024-05-01
    Get full text
    Article
  9. 9
    Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

    Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry by Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, Adam Sima, Jud Janak, Manish Patel, Huzefa Photowala, Vishvas Garg, Jerry Bagel

    Published 2024-12-01
    Get full text
    Article
  10. 10
    Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey

    Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey by Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda Stein Gold, Andrea Flower, Shauna Jardon, Yuri Klyachkin, Mark Lebwohl

    Published 2023-05-01
    Get full text
    Article
  11. 11
    Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials

    Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials by Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl

    Published 2023-06-01
    Get full text
    Article
  12. 12
    Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

    Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt

    Published 2024-06-01
    Get full text
    Article
  13. 13
    Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis

    Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis by Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt

    Published 2024-09-01
    Get full text
    Article
  14. 14
    Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey

    Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey by Brian S. Kim, Sonja Ständer, Kenji Kabashima, Jennifer A. Mohawk, Sherri So, Joana Goncalves, Nilam Shah, Catherine Munera, Joseph C. Punzalan, Romelia Argudo, Mark Lebwohl

    Published 2024-09-01
    Get full text
    Article
  15. 15
    Dermatologic findings in 2 patients with COVID-19

    Dermatologic findings in 2 patients with COVID-19 by Ryan Rivera-Oyola, MS, Merav Koschitzky, BA, Rachel Printy, PA-C, Stephanie Liu, DO, MBA, Roselyn Stanger, MD, Alexandra K. Golant, MD, Mark Lebwohl, MD

    Published 2020-06-01
    Get full text
    Article
  16. 16
    The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

    The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel by Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl

    Published 2024-02-01
    Get full text
    Article
  17. 17
    Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials

    Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials by Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, Howard Sofen, John Osborne, John Vaile, Ying-Ming Jou, Carolin Daamen, Julie Scotto, Thomas Scharnitz, Mark Lebwohl

    Published 2025-02-01
    Get full text
    Article
  18. 18
    Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

    Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) by Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl

    Published 2018-10-01
    Get full text
    Article
  19. 19
    Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

    Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials by Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B. Gottlieb, Philip J. Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, Victor Dong

    Published 2024-03-01
    Get full text
    Article
  20. 20
    Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

    Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Stu... by Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl

    Published 2023-05-01
    Get full text
    Article

Search Tools: